Clinical trials: Stage II Skin Cancer
Melanoma (Skin)
Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma
RATIONALE: Treating lymphocytes in the laboratory may help the lymphocytes kill more tumor cells when they are put back in the body. Aldesleukin may stimulate the lymphocytes to kill tumor cells.
- Trial name
- NCT00863330
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Melanoma, Squamous Cell Carcinoma of the Head and Neck
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle.
- Conditions
- Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin
- Trial name
- Hiltonol (NCT01984892)
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nina Bhardwaj
Breast Cancer
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
This study will test any good and bad effects of combining the study drugs pembrolizumab and olaparib, given before the standard surgical procedure, to treat TNBC or HR+ HER2- breast cancers.
- Trial name
- NCT05203445
- Testing
- Olaparib, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma (Skin)
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
RATIONALE: Pegylated arginine deiminase may stop the growth of tumor cells by taking away an amino acid needed for cell growth. PURPOSE: This phase II trial is studying how well pegylated arginine deiminase works in treating…
- Trial name
- NCT00450372
- Testing
- ADI-PEG-20, Pharmacology Studies
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Miami
Melanoma
Vaccination Plus Ontak in Patients With Metastatic Melanoma
The purpose of this study is to determine if an experimental melanoma vaccine can produce an immune response in patients with metastatic melanoma, and if combining this vaccine with the drug Ontak can improve these immune…
- Trial name
- NCT00515528
- Testing
- 4-peptide melanoma vaccine, Ontak
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Chicago
Breast Cancer
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01547741
- Testing
- Doxorubicin, Cyclophosphamide, Docetaxel
- Where
- 915 sites in United States, Puerto Rico
- Volunteers
- 4,242 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Denosumab for Breast Cancer With Bone Mets
The goal of this clinical research study is to learn if denosumab in combination with a hormonal drug can help lower the number of circulating tumor cells (CTCs) in patients with breast cancer that has spread to the bone.
- Trial name
- NCT01952054
- Testing
- Denosumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
This phase I trial studies the effects (good and bad) of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in treating patients with hormone receptor positive and HER2 negative breast cancer that has spread…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
- Trial name
- NCT03939897
- Testing
- Abemaciclib, Biopsy Procedure, Biospecimen Collection
- Where
- 14 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
RATIONALE: Vaccines may make the body build an immune response and decrease the recurrence of breast cancer. PURPOSE: Pilot trial to study the effectiveness of vaccine therapy in treating patients who are at high risk for breast…
- Trial name
- NCT00030823
- Testing
- Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine, QS21
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Melanoma, Metastatic Kidney Cancer
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
Background: Natural killer (NK) cells are large lymphocytes (a type of white blood cell) that are important in the immune response to cancer.
- Trial name
- NCT00328861
- Testing
- Natural Killer (NK) Lymphocytes, IL-2, Cyclophosphamide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00795769
- Testing
- ondansetron, survey administration, management of therapy complications
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer
A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer
This is an open-label, multi-center, non-randomized study of the safety and tolerability of the combination of T-DM1 plus docetaxel for the treatment of participants with metastatic breast cancer (MBC) and of T-DM1 plus docetaxel…
- Trial name
- NCT00934856
- Testing
- Docetaxel, Pertuzumab, Trastuzumab emtansine
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 98 people
- Sponsor
- Hoffmann-La Roche
Lupus Nephritis
Etanercept for the Treatment of Lupus Nephritis
Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease in which the body's immune system attacks its own normal tissues.
- Trial name
- NCT00447265
- Testing
- Etanercept, Lupus Treatment- Standard of Care
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Breast Neoplasms, Neoplasm Metastasis
Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer
The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer.
- Trial name
- NCT00319254
- Testing
- SKI-606 (Bosutinib)
- Where
- 15 sites in United States, Australia and 6 more
- Volunteers
- 75 people
- Sponsor
- Pfizer
Metastatic Breast Cancer, Thyroid Dysfunction
Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma
Up to one third of breast cancer patients have hypothyroidism or hyperthyroidism. L-thyroxine (T4), or Synthroid, is the most commonly prescribed agent for the management of hypothyroidism in the US.
- Trial name
- B-TREUH (NCT03787303)
- Testing
- Triiodothyronine (T3)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Aultman Health Foundation
Breast Cancer
Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
The purposes of this are: To determine the highest doses of Taxol and Navelbine that we can safely give to patients; To determine what kind of side effects are caused by the combination of Taxol, Navelbine and G-CSF; To determine…
- Trial name
- NCT00041470
- Testing
- Paclitaxel, Vinorelbine, Herceptin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Washington
Breast Cancer
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation plus biological therapy may allow the doctor…
- Trial name
- NCT00020722
- Testing
- therapeutic autologous lymphocytes, Ifosfamide, carboplatin, and etoposide (ICE) regimen, Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Breast Cancer, Metastatic Breast Cancer
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Subjects with advanced or metastatic (spread to other parts of the body) breast cancer that is HER2/neu-positive will take part in this study. This type of breast cancer has a high amount of a protein called HER2.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, HER2/Neu-positive Breast Cancer
- Trial name
- NCT00496366
- Testing
- Capecitabine, Lapatinib
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x rays to kill tumor cells.
- Trial name
- NCT01556243
- Testing
- therapeutic conventional surgery, whole breast irradiation
- Where
- 350 sites in United States
- Volunteers
- 270 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Breast Cancer, Stage IV Breast Cancer
Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estradiol can cause the growth of breast cancer.
- Trial name
- NCT00217399
- Testing
- sorafenib tosylate, anastrozole
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)